Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?

This article was originally published in The Pink Sheet Daily

Executive Summary

Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.


Related Content

FDA Guidance On Health Care Economic Data Is Coming In 2015
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
Rx Data Mining Opponents Will Need New Pitch After Supreme Court Strikes Down Vermont Law
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
FDA Off-Label Notice Stands, But Enforcement Still Vulnerable - Judge
Pearson Plaintiffs Using Shortened Omega-3 Qualified Claim
WLF Decision Could Discourage Publishing Of Studies To Avoid Piggybacking


Related Companies